Clearing
Clearing is a D2C healthcare platform offering comprehensive opioid-free care for America’s 50M+ chronic pain sufferers.
26 employees · est. 2020 · New York, United States
Olema Oncology is the older company (2020 vs 2007); Olema Oncology is the larger of the two.
2 signals in the last 90 days
Side-by-Side Comparison
| Metric | Clearing | Olema Oncology |
|---|---|---|
| Founded | ||
| Founded | 2020 | 2007 older |
| Headquarters | ||
| Headquarters | New York, United States | San Francisco, United States |
| Employees | ||
| Employees | 26 | 164 larger |
| Industry | ||
| Industry | Digital Health, Health Care, Health and Wellness | Biopharma, Biotechnology, Health Care |
| Funding Stage | ||
| Funding Stage | Seed | Post Ipo Equity |
| Total Funding | ||
| Total Funding | $20.00M | $325.05M |
| Funding Rounds | ||
| Funding Rounds | 1 | 5 |
| Services | ||
| Services | Not tracked yet | Not tracked yet |
| Target Customers | ||
| Target Customers | Not tracked yet | Not tracked yet |
| Taxonomy | ||
| Taxonomy | D2C Healthcare Platform, Chronic Pain Relief, Digital Healthcare, Opioid-free Care, Physician Partnership, Research Collaboration, Funding, Venture Capital, Consumer Healthcare, Top-tier Investors, Entrepreneurship, Pain Management, Medical Research | Biopharmaceutical Company, Targeted Therapies, Women's Cancers, OP-1250, Estrogen Receptor Antagonist, Breast Cancer Treatment, Phase 1/2 Clinical Trial, Healthcare Investors, Pharmaceutical Development, Innovative Therapies, Clinical Research, Oncology, Biotech, Scientific Research |
| Website | ||
| Website | clearing.com | olema.com |
About Clearing
Clearing is a pioneering D2C healthcare platform dedicated to providing opioid-free care for chronic pain sufferers in the United States. Since its founding in 2020, the company has positioned itself at the forefront of digital health by collaborating with esteemed medical institutions such as Harva...
About Olema Oncology
Olema Oncology is a biopharmaceutical company that focuses on developing innovative targeted therapies for women's cancers. Their lead program, OP-1250, is a potential best-in-class complete estrogen receptor antagonist (CERAN) designed to treat estrogen receptor-positive (ER+), human epidermal grow...
Be first to know when either one moves
Funding rounds, hiring surges, leadership changes and stack switches at Clearing and Olema Oncology — tracked continuously, sent the day they land.
Funding, hiring, leadership and stack changes at Clearing and Olema Oncology — by email.
Frequently Asked Questions
Compare Clearing with someone else
Start typing a company name or domain.